多西他赛、顺铂和氟尿嘧啶分剂量新辅助化疗用于食管癌鳞状细胞癌患者
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
作者信息
Ojima Toshiyasu, Nakamori Mikihito, Nakamura Masaki, Katsuda Masahiro, Hayata Keiji, Kato Tomoya, Kitadani Junya, Tabata Hirotaka, Takeuchi Akihiro, Iwahashi Makoto, Yamaue Hiroki
机构信息
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
出版信息
Anticancer Res. 2016 Feb;36(2):829-34.
BACKGROUND
The aim of this phase II study was to evaluate the feasibility of a neoadjuvant chemotherapy regimen consisting of divided-dose docetaxel and cisplatin, with 5-fluorouracil (NAC-DCF), for treatment of patients with stage II/III squamous cell carcinoma of the esophagus (SCCE).
PATIENTS AND METHODS
The NAC-DCF regimen, consisting of 2-h infusion of docetaxel at 35 mg/m(2) on days 1 and 8, 4-h infusion of cisplatin at 12 mg/m(2) on days 1-5, and continuous infusion of 5-fluorouracil at 600 mg/m(2) on days 1-5, was administered. We compared NAC-DCF with conventional NAC-CF.
RESULTS
The DCF group comprised of 45 patients, and the CF group comprised of 28 patients. The incidence of grade 3/4 neutropenia was significantly higher in the DCF group (56%) than in the CF group (0%). Grade 2/3 pathological response was attained in a significantly higher percentage of patients in the DCF group (40%) than in the CF group (11%) (p=0.0153).
CONCLUSION
This DCF regimen led to a high frequency of pathological responses among patients with advanced SCCE.
背景
本II期研究的目的是评估由分剂量多西他赛和顺铂联合5-氟尿嘧啶组成的新辅助化疗方案（NAC-DCF）治疗II/III期食管鳞状细胞癌（SCCE）患者的可行性。
患者与方法
给予NAC-DCF方案，即第1天和第8天静脉滴注多西他赛35mg/m²，持续2小时；第1 - 5天静脉滴注顺铂12mg/m²，持续4小时；第1 - 5天持续静脉滴注5-氟尿嘧啶600mg/m²。我们将NAC-DCF与传统的NAC-CF进行了比较。
结果
DCF组有45例患者，CF组有28例患者。DCF组3/4级中性粒细胞减少的发生率（56%）显著高于CF组（0%）。DCF组达到2/3级病理缓解的患者百分比（40%）显著高于CF组（11%）（p = 0.0153）。
结论
这种DCF方案在晚期SCCE患者中导致了较高频率的病理缓解。
Zotero 插件